

COVID-19 has caused a global health crisis with over 776 million cases and 7 million deaths as of 2024. Despite vaccines reducing severe cases, treatment options remain critical for mitigating hospitalizations and mortality, particularly against evolving variants. Two widely used antivirals—Paxlovid and Azvudine—are central to current treatment protocols. However, their comparative efficacy and safety have been unclear until now.
A recent multicenter study, published in Signal Transduction and Targeted Therapy, reveals that Azvudine not only reduces all-cause mortality but also presents fewer adverse effects compared to Paxlovid.
Azvudine Study Overview
Study Design
The research was conducted in Henan and Xinjiang provinces, China, and involved:
- 37,606 hospitalized COVID-19 patients from 10 hospitals in Henan.
- 3,270 patients from a hospital in Xinjiang for additional validation.
Patients received eitherAzvudine or Paxlovid alongside standard care. Propensity score matching (PSM) was applied to balance demographic and clinical characteristics between groups.
Key Findings
Efficacy Outcomes
- Mortality Reduction:
- Azvudine significantly reduced all-cause mortality (Hazard Ratio [HR]: 0.82, p = 0.036).
- 469 deaths were recorded: 288 in the Azvudine group vs. 181 in the Paxlovid group.
- Composite Disease Progression:
- No significant difference between the two groups (HR: 1.15, p = 0.097).
- Delayed Treatment:
- Patients starting treatment 5+ days after diagnosis saw greater benefits with Azvudine (HR: 0.56).
- Patients with Malignant Tumors:
- Azvudine provided notable advantages for these patients (HR: 0.33).
Safety Outcomes
This drug demonstrated fewer adverse events (AEs), particularly mild to moderate (grades 1 and 2), compared to Paxlovid, making it a safer alternative for hospitalized patients.
Antitumor Potential of Azvudine
In addition to its antiviral properties, Azvudine exhibited promising antitumor effects, including:
- Suppressing hepatocellular carcinoma cell proliferation.
- Enhancing immune responses, which could benefit COVID-19 patients with liver cancer.
Implications for COVID-19 Management
The findings support the use of Azvudine as a first-line treatment for:
- Hospitalized COVID-19 patients, particularly those with delayed treatment initiation.
- Patients with comorbidities, such as malignancies.
Azvudine’s dual benefits—lower mortality risk and antitumor effects—position it as a versatile option in the fight against COVID-19 and associated complications.
Future Directions
- Broader Validation: Further trials are needed to confirm these findings across diverse populations.
- Biomarker Studies: Identifying subgroups that would benefit most from Azvudine treatment.
- Antitumor Applications: Exploring its potential in oncology beyond the antiviral use.
Takeaway
Azvudine outperforms Paxlovid in reducing COVID-19 mortality, with fewer side effects and added antitumor benefits. These findings highlight the drug’s potential as a safer and more effective treatment, particularly for vulnerable patient populations.
More Information: Wang, H., Cui, G., Cheng, M. et al. (2025) Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Sig Transduct Target Ther. doi: https://doi.org/10.1038/s41392-025-02126-w. https://www.nature.com/articles/s41392-025-02126-w
more recommended stories
Brain’s High-Tech Fix for Blurry Vision During Movement
High-Tech Video Optimization in Our Brain:.
Air Pollution Hurts Brain Health in Just 4 Hours
Air Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disorders
Urgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences Division
The High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences Division
The installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences Division
Scientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences Division
Antimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences Division
The TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences Division
The research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences Division
Only 30 prizes are awarded throughout.
Leave a Comment